• March 30, 2016
    FLORHAM PARK, N.J., March 30, 2016 — Zoetis Inc. today announced that the U.S. Department of Agriculture (USDA) has granted the company a conditional license for Avian Influenza Vaccine, H5N1 Subtype, Killed Virus*. The vaccine is intended for use in chickens as an aid in the prevention of disease caused by avian influenza H5N1.“We stand ready to help our customers implement a vaccination strategy, should the USDA determine that is the best course of action for the industry,” said Jonmore...
  • March 23, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the global leader in animal health, today announced that it has been named one of America’s Best Midsize Employers in 2016 by Forbes Magazine. Zoetis is the only pharmaceutical company focused solely on animal health to make the list, and is ranked #81 out of 250 midsize companies. “This honor is a terrific recognition of the workplace, culture and brand we have built at Zoetis since becoming anmore...
  • March 4, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies Animal Health Summit on Thursday, March 31, 2016, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:00 p.m. EDT. The presentation is not scheduled to be webcast. Investors and other interested parties will be able to access the presentation materials at http://investor.more...
  • March 1, 2016
    FLORHAM PARK, N.J. - March 1, 2016 - Zoetis today announced the launch of CLARIFIDE® Plus, the first commercially available, U.S.-based genomic test that gives dairy producers the ability to directly predict disease risk in Holstein cattle.CLARIFIDE Plus includes new genomic predictions for wellness traits that provide direct indication of the genetic risk factors for six of the most common and costly animal health challenges on dairies. CLARIFIDE Plus also includes an exclusive newmore...
  • February 25, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved SimparicaTM (sarolaner) Chewables to kill adult fleas and prevent flea infestations, as well as treat and control tick infestations due to the Lone Star tick, the Gulf Coast tick, the American dog tick, and the brown dog tick. Simparica is approved for use in dogs 6 months of age or older and weighing 2.8 pounds or more. In a single-dose, tastymore...
  • February 23, 2016
    PUERTO MONTT, CHILE - PHARMAQ's vaccine ALPHA JECT LiVac® SRS received a provisional marketing authorisation (PMA number 2320-BP) from the Chilean authority, Servicio Agrícola y Ganadero de Chile (SAG). "Our innovative drive is based on the aquaculture industry's need to produce safe and healthy seafood. We are confident that this ground-breaking vaccine will be an important tool to help fight SRS. This is a highly requested product by the industry and will help achieve more predictable andmore...
  • February 19, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a second quarter 2016 dividend payable to holders of the company’s common stock of $0.095 per share. The dividend is to be paid on Wednesday, June 1, 2016, to holders of record on Thursday, April 7, 2016. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on moremore...
  • February 17, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Barclays Global Healthcare Conference on Wednesday, March 16, 2016, in Miami, Fla. Clint Lewis, Executive Vice President and President, International Operations, will represent the company and respond to questions from analysts. He is scheduled to present at 9:00 a.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation bymore...
  • February 16, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2015 and updated its guidance for full year 2016 and 2017. The company reported revenue of $1.3 billion for the fourth quarter of 2015, a decrease of 3% from the fourth quarter of 2014. Revenue reflected an operational1 increase of 6%, excluding the impact of foreign currency. Net income for the fourth quarter of 2015more...
  • January 12, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) provided the following statement concerning the European Commission’s decision regarding existing tax rulings in Belgium, and gave its implications for the company’s financial guidance for 2016 and 2017: Zoetis is disappointed with the European Commission’s announcement regarding Belgium’s tax rulings and its implications for Zoetis. The company complies with all tax laws and has relied on these long-standingmore...